Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 105

Immune Response Laboratories DNA Virus 105

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants primarily help the immune response through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.” This involves the use of CAR-T cell products derived from donor T cells, hence the term “off the shelf,” making it easier to standardise treatments.

Therapies 64

Therapies Treatment Vaccine FDA Approval 64

PLOS: DNA Science

SEPTEMBER 5, 2024

Diagnosis began to shift from a body-part basis to a molecular one, which I wrote about in “Mutation and location important in cancer treatment” for The Lancet in 2015. This removes the cancer’s blocking of the immune response, so that T cells can fight the cancer.

Treatment 71

Treatment FDA Approval DNA Small Molecule 71

Drug Target Review

JULY 7, 2023

In pregnant individuals, maternal autoantibodies can even attack the organs and tissues of the foetus, 1-9 Many of these diseases are rare, with no safe, targeted, advanced and effective treatment options approved for patients in need. Targeted therapies are designed to interfere with, or target, molecules such as proteins within the body.

Disease 98

Disease Immune Response Therapies Treatment 98

LifeSciVC

MAY 9, 2024

Take Janux Therapeutics, a biotech focused on developing immunotherapies that generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue. While early, these data demonstrate clear promise to advance this modality.

Immune Response 76

Immune Response Vaccine Therapies Clinical Development 76

Olympian Clinical Research

NOVEMBER 9, 2022

Therefore, if you or a loved one is dealing with this rare condition, it’s essential to educate yourself about the condition and its potential treatments. The more you know, the better equipped you’ll be to make informed decisions about your care. Bullous Pemphigoid Risk Factors and Causes.

Treatment 52

Treatment Clinical Research Immune Response Therapies 52

Drug Target Review

JUNE 6, 2023

In this IO arena, we continue to search for additional treatments that can further benefit patients. Generally, IO has been focused on harnessing the anti-tumour activity of certain cancer-fighting T-cells , a key cell type involved in the adaptive immune defense system.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

The Pharma Data

MARCH 9, 2021

Ongoing Phase III studies in non-small cell lung cancer continue, evaluating canakinumab in earlier treatment settings. Pro-tumor inflammation enables tumor development by driving cancer-causing processes and by suppressing anti-tumor immune responses 9,10. Canakinumab is a first-in-class interleukin-1beta (IL-1?)

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) has granted orphan drug designation status to APX005M for the treatment of esophageal and gastroesophageal junction cancer and for the treatment of pancreatic cancer. APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. SAN CARLOS, Calif. ,

Treatment 40

Treatment Immune Response Clinical Trials Clinical Development 40

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 103

Therapies Clinical Trials Immune Response Trials 103

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

The Pharma Data

OCTOBER 9, 2021

years of exposure 3 Design of a new open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in MS-patients treated with Kesimpta 4 , and new findings from open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in secondary progressive MS (SPMS) patients treated with Mayzent will be presented 5.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

The Pharma Data

DECEMBER 31, 2020

31, 2020 — Blood vessel damage and inflammation in the brains of deceased COVID-19 patients suggest the damage is not caused by the virus, but the body’s immune response to it. The spots were surrounded by T cells — signs of an immune response. Further Support and Information on COVID-19. THURSDAY, Dec.

Immune Response 52

Immune Response Virus Doctors Research 52

The Pharma Data

OCTOBER 6, 2021

years of exposure 3 Design of a new open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in MS-patients treated with Kesimpta 4 , and new findings from open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in secondary progressive MS (SPMS) patients treated with Mayzent will be presented 5.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. Results of the Phase 2 trial will inform the Phase 3 protocol. GSK is also exploring potential therapeutic or treatment options for COVID-19 patients. About the Phase 2 study.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

MARCH 8, 2022

While the development of vaccines was accomplished in a remarkably short timeframe, the identification of direct antiviral treatments has progressed comparatively slowly. In the light of the further risk of pandemics in the future, however, there remains need for direct antiviral drugs and treatments.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

JANUARY 5, 2021

.” The clinical trial involved 24 COVID patients at one of two Miami-area hospitals who had developed severe acute respiratory distress syndrome, a condition in which the body’s immune response to a serious infection causes the lungs to fill with fluid. “Is this a scalable type of intervention?”

Immune Response 52

Immune Response Hospitals Clinical Trials Trials 52

Drug Target Review

APRIL 3, 2024

Our research demonstrated that GDF-15 acts as a versatile tool for tumours to inhibit the mounting of an effective antitumoral immune response at various steps of its process, including antigen presentation, immune cell activation, and their migration and infiltration into the tumour.

Science 105

Science Clinical Development Treatment DNA 105

The Pharma Data

SEPTEMBER 25, 2020

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. Immune Response Data. Source link.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Drug Target Review

JANUARY 15, 2024

Monoclonal antibodies (mAbs) targeting tumour-specific antigens play an essential role in the treatment of many cancers. The Class I HLA system presents fragments of intracellular antigens to CD8 T cells and allows the immune system to monitor intracellular events, thus providing an essential component of immunity against cancer.

Engineering 110

Engineering DNA Virus Immune Response 110

The Pharma Data

DECEMBER 18, 2020

Epinephrine should serve as the first-line treatment for any anaphylactic reactions. “Physicians and other providers should inform such immunocompromised patients of the possibility of a diminished immune response to the vaccine. ” More Information. Further Support and Information on COVID-19.

Vaccine 52

Vaccine Immune Response Treatment Drugs 52

DrugBank

MAY 6, 2024

Unlike conventional chemical-based medicines, biologics offer targeted therapies derived from living cells, which can result in more effective and personalized treatments. This surge in approvals clearly marks a new era in healthcare, emphasizing the rapid progress and heightened focus on biologics in medical treatment.

FDA Approval 65

FDA Approval Therapies Treatment Clinical Trials 65

The Pharma Data

NOVEMBER 22, 2020

The TALON effector modules are based on immunomodulatory molecules that act as regulatory control points within the immune system. In conjunction with a tissue-specific targeting moiety, the effectors create novel bifunctional molecules for the treatment of autoimmune and inflammatory diseases. Source link.

Immune Response 52

Immune Response Engineering Clinical Research Disease 52

The Pharma Data

OCTOBER 23, 2020

A solidarity clinical trial “is one of the largest international randomized trials for Covid-19 treatments, enrolling almost 12,000 patients in 500 hospital sites in over 30 countries”, according to the World Health Organization (WHO), which launched the trail with a number of partners.

Trials 52

Trials Immune Response Hospitals Clinical Trials 52

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Immune response was measured using immunoglobulin G (IgG) assays. Approximately 92 percent of participants in the analysis received an mRNA vaccine. Chief Medical Officer at Biogen.

Vaccine 52

Vaccine Therapies Disease Immune Response 52

Drug Target Review

JUNE 1, 2023

The research identifies the vulnerable sites on the spike protein that can be targeted by human antibodies, providing valuable information for the development of future vaccines and antibody treatments. Preclinical studies in mice suggest that some of these antibodies may also be effective in preventing severe cases of COVID-19. “To

Virus 97

Virus Vaccine Immune Response Research 97

PLOS: DNA Science

MAY 16, 2024

• identifies parts of the virus to target to provoke an immune response from a vaccine. • reveals viral vulnerability to inspire novel treatments. ” This information can inform design of vaccines, therapeutics, and public health measures, which can help prevent epidemics from flaring up.

Virus 98

Virus DNA RNA Vaccine 98

The Pharma Data

MARCH 8, 2021

Ongoing Phase III studies in non-small cell lung cancer continue, evaluating canakinumab in earlier treatment settings. Pro-tumor inflammation enables tumor development by driving cancer-causing processes and by suppressing anti-tumor immune responses 9,10. Canakinumab is a first-in-class interleukin-1beta (IL-1?) Disclaimer.

Immune Response 52

Immune Response Clinical Trials Trials Treatment 52

The Pharma Data

JANUARY 12, 2021

It is being developed for the treatment of solid tumors. Dr. Ben-Moshe told BioSpace that BND-22 differs from traditional immunotherapy in that it can elicit a more total immune response. . “It It is a new immune checkpoint that is expressed on three different immune cells: Macrophages, [Natural Killer] NK cells, and T cells. [It]

Immune Response 52

Immune Response Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. More information. MONDAY, Jan.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52

NIH Director's Blog: Drug Development

DECEMBER 15, 2020

What’s been missing is a one-stop online information portal that pulls together the most current information for people of all groups, races, ethnicities, and backgrounds who want to get involved in fighting the pandemic. All of these are promising treatments, but need to be rigorously tested to be sure they are safe and effective. •

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

NOVEMBER 12, 2020

José Baselga, Executive Vice President, Oncology R&D, said: “Since the beginning of the year, AstraZeneca has been committed to doing everything we can to respond to COVID-19, including investigating existing medicines as potential treatments. Calquence® (acalabrutinib) [prescribing information]. Further information.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

The Pharma Data

APRIL 8, 2021

Additionally, research across multiple presentations will highlight novel technologies that enable early detection of disease recurrence to inform earlier interventions for patients who are more likely to benefit from treatment.

DNA 52

DNA Immune Response Therapies Treatment 52

The Pharma Data

JANUARY 18, 2021

Next Generation AAVs enhance gene therapies by increasing transduction efficiency and specificity while reducing immune responses and cost. Both parties aim to build a strategic partnership for long term success which will bring accessible AAV gene therapy treatment to patients around the world.”

Therapies 52

Therapies Immune Response DNA Treatment 52

The Pharma Data

JUNE 26, 2021

We believe that mRNA technology could have several advantages for a seasonal flu application including the potential ability to demonstrate robust immune responses based on preclinical data to date, enable antigen specificity within a short timeframe from seasonal virus strain selection, and deploy agile manufacturing capacity.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. gammadelta T cells link innate and adaptive immune responses. A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas. Cells 9(40):800 (2020).

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

DECEMBER 22, 2020

All anaphylactic reactions should be managed immediately with epinephrine as the first-line treatment, the experts advised in a college news release. The mRNA COVID-19 vaccines are not live vaccines and can be given to people with weakened immune systems. Further Support and Information on COVID-19. © 2020 HealthDay.

Vaccine 52

Vaccine Immune Response Treatment Disease 52